Although EVE has been widely used in the management of pancreatic and other neuroendocrine neoplasms, there are only seven published cases of pituitary tumors treated with EVE combination therapy (three ACTH secreting carcinomas, one PRL secreting adenoma, and three not stated) (11, 25–27, 58) (Table 4). The gene discussed is PRL; the disease is carcinoma.